Targacept TRGT
-
REFILE-UPDATE 1- Targacept cuts 46 pct jobs, to focus on key drugs
April 25 (Reuters) - Targacept Inc cut 46 percent of its workforce to focus on the development of its most advanced drug pipeline.
-
Targacept (TRGT) -10.3% premarket after announcing revised top-line results from its exploratory Phase 2 study of TC-6987 in asthma show it no longer achieves protocol-defined success criteria on the ...
Targacept ( TRGT ) -10.3% premarket after announcing revised top-line results from its exploratory Phase 2 study of TC-6987 in asthma show it no longer achieves protocol-defined success criteria on the primary endpoint of Forced Expiratory Volume. Post your comment!
-
Seth Klarman bails out of Targacept (TRGT), an amended 13G indicating Baupost Group exited its position at Q1's end. The move was almost certainly driven by the ending of development of Targacept's ...
Seth Klarman bails out of Targacept ( TRGT ), an amended 13G indicating Baupost Group exited its ..... move was almost certainly driven by the ending of development of Targacept 's diabetes drug , along with AstraZeneca giving up on an anti …
-
UPDATE 1- Targacept reports mixed data from two trials
March 27 (Reuters) - Targacept said an experimental drug proved effective in a mid-stage asthma trial, but failed to meet the main goal in another trial for type 2 diabetes.
-
Shares of Targacept (TRGT) fall 5.0% in premarket trading after the company announces that it will discontinue a clinical trial of its TC-5214 treatment for depression and releases disappointing ...
Shares of Targacept ( TRGT ) fall 5.0% in premarket trading after the company announces that it will discontinue a clinical trial of its TC-5214 …
-
Nothing About Targacept's Fundamental Story Has Changed, But It Is 30% Cheaper
By Bryce Istvan : Targacept ( TRGT ) sold off as much as 30% on ..... that announcement on December 20th, Targacept shares hit a 52 week low of $4.92 ..... the $7.50 level on the strength of Targacept 's neuronal nicotine receptor based …
-
AstraZeneca gives up on Targacept antidepressant
LONDON (Reuters) - AstraZeneca has thrown in the towel on an experimental antidepressant targeting nicotine receptors after the drug licensed from Targacept failed in two remaining clinical trials,...
-
Targacept (TRGT) -15% premarket after the antidepressant it was testing with AstraZeneca (AZN) failed in its last two late-stage studies, ending plans to seek regulatory approval. The two companies ...
Targacept ( TRGT ) -15% premarket after the antidepressant it was testing with AstraZeneca ( AZN ) failed in its last two late-stage …
-
Targacept (TRGT): Q4 EPS of -$0.29 beats by $0.01. Revenue of $18.9M (-19.2% Y/Y) misses by $1.3M. (PR)
Targacept ( TRGT ): Q4 EPS of -$0.29 beats by $0.01 . Revenue of $18.9M (-19.2% Y/Y) misses by $1.3M . ( PR ) Post your comment!
-
4 Big Buys And 1 Big Sell By Seth Klarman
… examined the biggest 4 buys, and 1 big sell from a fundamental perspective, adding my opinion about them. Click to enlarge Company Name Ticker Shares Held % Change in Shares % of Portfolio YTD Return Targacept Inc. Complete Story »